CRIS Curis Inc.

0.71
-0.04  -5%
Previous Close 0.74
Open 0.75
Price To Book -0.76
Market Cap 25,863,692
Shares 36,582,309
Volume 144,909
Short Ratio
Av. Daily Volume 139,553
Stock charts supplied by TradingView

NewsSee all news

  1. Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

    LEXINGTON, Mass., March 19, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results

  2. Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

    LEXINGTON, Mass., March 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will

  3. Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

    LEXINGTON, Mass., Feb. 27, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered

  4. Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

    LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered

  5. Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

    LEXINGTON, Mass. and NEW YORK, Jan. 13, 2020 /PRNewswire/ -- Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data due later in 2020.
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 data to be presented at SITC 2019. However, further enrolment is not planned due to insufficient efficacy.
CA170
Solid Tumors and Lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Development to be discontinued - noted March 19, 2020.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)
Phase 1a/1b trial to be initiated 2H 2020.
CI-8993

Latest News

  1. Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

    LEXINGTON, Mass., March 19, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results

  2. Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

    LEXINGTON, Mass., March 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will

  3. Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

    LEXINGTON, Mass., Feb. 27, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered

  4. Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

    LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered

  5. Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

    LEXINGTON, Mass. and NEW YORK, Jan. 13, 2020 /PRNewswire/ -- Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based

  6. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2,

  7. Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

    LEXINGTON, Mass., Jan. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered

  8. Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

    LEXINGTON, Mass., Dec. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary

  9. Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

    LEXINGTON, Mass., Dec. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary

  10. Curis to Present at 31st Annual Piper Jaffray Healthcare Conference

    LEXINGTON, Mass., Nov. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  11. Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass., Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that abstracts for both

  12. Curis Reports Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial

  13. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1,

  14. Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  15. Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

    LEXINGTON, Mass., Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill